Juliane Rascher

Jun 9, 2024 | bpspubs.onlinelibrary.wiley.com | Juliane Rascher |Dan Cotton |Sebastian Haertter |Martina Brueckmann

What is already known about this subject Empagliflozin is approved for use in adults with T2D at a dose of 10 mg once daily with potential increase to 25 mg, HF independent of left ventricular ejection fraction, and chronic kidney disease at a dose of 10 mg once daily. Empagliflozin systemic exposure is similar between patients with T2D and healthy subjects at equivalent dose levels.